Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial. We sough...

Source: Cardiovascular Diabetology - June 18, 2022 Category: Cardiology Authors: Magnus O. Wijkman, Brian Claggett, Muthiah Vaduganathan, Jonathan W. Cunningham, Rasmus R ørth, Alice Jackson, Milton Packer, Michael Zile, Jean Rouleau, Karl Swedberg, Martin Lefkowitz, Sanjiv J. Shah, Marc A. Pfeffer, John J. V. McMurray and Scott D. S Tags: Research Source Type: research